Indianapolis, IN, United States of America

Michael Patrick Akers

USPTO Granted Patents = 6 


 

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 21(Granted Patents)


Company Filing History:


Years Active: 2018-2024

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Michael Patrick Akers: Innovator in Rapid-Acting Insulin Compositions

Introduction

Michael Patrick Akers is a notable inventor based in Indianapolis, IN (US), recognized for his contributions to the field of diabetes management through innovative insulin formulations. With a total of six patents to his name, Akers has made significant strides in improving the pharmacokinetic and pharmacodynamic properties of insulin.

Latest Patents

Akers' latest patents focus on rapid-acting insulin compositions. These inventions consist of human insulin or insulin analogs that incorporate specific concentrations of citrate and chloride. In some formulations, sodium chloride, zinc, and optionally magnesium chloride and/or surfactants are included. The result is a composition that exhibits faster action compared to existing commercial insulin analog products.

Career Highlights

Throughout his career, Akers has worked with prominent companies in the pharmaceutical industry, including Eli Lilly and Company and Stelis Biopharma Private Limited. His experience in these organizations has contributed to his expertise in developing advanced insulin therapies.

Collaborations

Akers has collaborated with several professionals in his field, including Chi Arch Nguyen and Chad Donald Paavola. These partnerships have likely enhanced his research and development efforts in creating effective insulin compositions.

Conclusion

Michael Patrick Akers stands out as an influential inventor in the realm of rapid-acting insulin formulations. His innovative work continues to impact diabetes treatment and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…